[Cost-utility analysis of triple therapy with telaprevir in treatment-naive hepatitis C patients]
Buti M, Gros B, Oyaguez I, Andrade RJ, Serra MA, Turnes J, Casado MA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
25344136

DOI
10.7399/fh.2014.38.5.7640

Indexing Status
Subject indexing assigned by CRD

MeSH
Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Cost-Benefit Analysis; Markov Chains; Polyethylene Glycols; Oligopeptides; Recombinant Proteins; Ribavirin; Survival Analysis; Fibrosis; Drug Costs; Spain

AccessionNumber
22014039759

Date bibliographic record published
24/02/2015